SEHK:512Pharmaceuticals
Assessing Grand Pharmaceutical Group (SEHK:512) Valuation After China Drug Approvals And Earnings Update
Grand Pharmaceutical Group (SEHK:512) has had a busy stretch, securing China approval to commercialize eye treatment GPN01768, advancing migraine drug GPN01020 into Phase II trials, reporting full year 2025 earnings, and updating its dividend.
See our latest analysis for Grand Pharmaceutical Group.
The recent China approvals for GPN01768 and the Phase II go ahead for GPN01020 come as the share price trades at HK$7.22, with a 7 day share price return of 6.49% but a 90 day share price return...